TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8887038

Group type: EXPERIMENTAL
Intervention: High-dose intraperitoneal aprotinin treatment (aprotinin group, n = 22)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group (n = 26, not treated with aprotinin)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (aprotinin and control)
Number of subjects: 48
Study: 1818424

Group type: EXPERIMENTAL
Intervention: IFN maintenance therapy (3 x 10(6) I.U. INTRON‐A by subcutaneous injection three times a week for 4 months)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Vitamins (control group)
Number of subjects: 21
Study: 7193447

Group type: EXPERIMENTAL
Intervention: Sequential administration of methotrexate (50 mg/sq m orally) and cisplatin (intravenously 24 hours later), repeated four times at weekly intervals.
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Therapeutic postoperative radiation therapy (for 43 patients operated on).
Number of subjects: 82

Group type: COMPARATOR
Intervention: Observation only (for patients randomly selected after surgery and/or radiation therapy).
Number of subjects: 82
Study: 31901082

Group type: EXPERIMENTAL
Intervention: Extra virgin olive oil (EVOO)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Canola oil
Number of subjects: 40
Study: 31222909

Group type: EXPERIMENTAL
Intervention: Waist circumference (WC)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio (WHtR)
Number of subjects: 925

Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Adding WC or WHtR on top of BMI
Number of subjects: 925
Study: 28052570

Group type: EXPERIMENTAL
Intervention: Youth Fit 4 Life (YF4L) treatment group
Number of subjects: 141

Group type: COMPARATOR
Intervention: Control group (typical care)
Number of subjects: 141
Study: 25724784

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 1829

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass grafting (CABG)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Composite event of death (D) and nonfatal Q-wave myocardial infarction (MI)
Number of subjects: 1829

Group type: COMPARATOR
Intervention: Nonfatal MI
Number of subjects: 1829
Study: 25111438

Group type: EXPERIMENTAL
Intervention: Carbon dioxide ablative fractional laser (AFL)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Pulsed dye laser (PDL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Both PDL and AFL
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall improvement measured by the Vancouver Scar Scale
Number of subjects: 14
Study: 18248343

Group type: EXPERIMENTAL
Intervention: Free semiannual preventive dental care
Number of subjects: 498
Study: 15020036

Group type: EXPERIMENTAL
Intervention: simvastatin 20 mg
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: pravastatin 40 mg
Number of subjects: 1000

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 1000
Study: 11740295

Group type: EXPERIMENTAL
Intervention: Acetylsalicylic acid (ASA) 800 mg, administered two times daily for 3 days before exercise tests
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 9228503

Group type: EXPERIMENTAL
Intervention: Beighton score measurement in group I (n = 252)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Beighton score measurement in group II (n = 658)
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Comparison of hypermobility between genders in group II
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Age-related hypermobility assessment
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Assessment of hypermobility at non-dominant body side
Number of subjects: 910

Group type: EXPERIMENTAL
Intervention: Quetelet-index relation to hypermobility
Number of subjects: 910
Study: 8093705

Group type: EXPERIMENTAL
Intervention: 50 micrograms salmeterol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 3307414

Group type: EXPERIMENTAL
Intervention: Diclofenac 100 mg/day
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 11320918

Group type: EXPERIMENTAL
Intervention: Automated core biopsy
Number of subjects: 52

Group type: COMPARATOR
Intervention: Fine needle aspiration cytology
Number of subjects: 52
Study: 31537908

Group type: EXPERIMENTAL
Intervention: Bevacizumab and trabectedin every 21 days (Arm BT)
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Bevacizumab, trabectedin and carboplatin every 28 days (Arm BT+C)
Number of subjects: 71
Study: 30302441

Group type: EXPERIMENTAL
Intervention: Supra-nanofilled composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Nanofilled composite
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Microhybrid composite
Number of subjects: 40

Group type: COMPARATOR
Intervention: Dental tissues
Number of subjects: 40
Study: 26646759

Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel (40 mg/day; 80 mg/m²/week)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Single-agent chemotherapy
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Afatinib plus paclitaxel
Number of subjects: 202
Study: 25089351

Group type: EXPERIMENTAL
Intervention: Omega-3 supplementation (docosahexaenoic acid and eicosapentaenoic acid)
Number of subjects: 36

Group type: COMPARATOR
Intervention: No omega-3 supplementation
Number of subjects: 36

Group type: COMPARATOR
Intervention: Anti-VEGF treatment-naïve
Number of subjects: 36

Group type: COMPARATOR
Intervention: Epiretinal membrane or macular hole
Number of subjects: 36
Study: 22348256

Group type: COMPARATOR
Intervention: Dabigatran etexilate 150 mg alone (treatment A)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 7 days of rifampicin (treatment B)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 7 days washout (treatment C)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate after 14 days washout (treatment D)
Number of subjects: 24
Study: 20801444

Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Manual vacuum aspiration (MVA)
Number of subjects: 0
Study: 17078981

Group type: EXPERIMENTAL
Intervention: Tyrosine (300 mg/kg body weight)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo (no tyrosine)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Cold water trials (both TYR and PLB)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (warm water at 35 degrees C)
Number of subjects: 15
Study: 16215602

Group type: EXPERIMENTAL
Intervention: Essential fatty acids supplement for 8 weeks
Number of subjects: 55

Group type: COMPARATOR
Intervention: Placebo supplement for 8 weeks
Number of subjects: 55
Study: 12164090

Group type: EXPERIMENTAL
Intervention: Amlodipine (2 months treatment)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Vitamin C (intra-arterial infusion)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Co-infusion of L-NMMA (inhibitor of nitric oxide synthase)
Number of subjects: 8
Study: 9931520

Group type: EXPERIMENTAL
Intervention: Fentanyl (10.5 microg/kg over a 1-hour period followed by 1.5 microg/kg/hr)
Number of subjects: 163

Group type: COMPARATOR
Intervention: Morphine (140 microg/kg over a 1-hour period followed by 20 microg/kg/hr)
Number of subjects: 163

Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 163

Group type: COMPARATOR
Intervention: Morphine
Number of subjects: 163
Study: 9454229

Group type: EXPERIMENTAL
Intervention: Patients with larynx carcinoma
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy persons
Number of subjects: 30
Study: 1968694

Group type: EXPERIMENTAL
Intervention: Alcuronium (0.03 mg/kg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Tubocurarine (0.05 mg/kg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.01 mg/kg)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Atracurium (0.04 mg/kg)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Isoflurane (control)
Number of subjects: 250
Study: 373959

Group type: EXPERIMENTAL
Intervention: Diagnostic standardization procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Examiner variance monitoring
Number of subjects: 0
Study: 31648505

Group type: EXPERIMENTAL
Intervention: Enhanced recovery after surgery (ERAS) protocol including electrolyte solution administration, intraoperative warming, controlled infusion volume, and multi-mode analgesia.
Number of subjects: 86

Group type: COMPARATOR
Intervention: Traditional interventions (Control group).
Number of subjects: 86
Study: 27445072

Group type: COMPARATOR
Intervention: Dorzolamide/timolol fixed combination (group A)
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Brinzolamide/brimonidine fixed combination (group B)
Number of subjects: 44
Study: 26522035

Group type: EXPERIMENTAL
Intervention: Forsus Fatigue Resistant Device (FFRD) alone
Number of subjects: 32

Group type: COMPARATOR
Intervention: Mini-implant anchored Forsus Fatigue Resistant Device (FMI)
Number of subjects: 32
Study: 23377333

Group type: EXPERIMENTAL
Intervention: Scar product (twice-daily application)
Number of subjects: 28

Group type: COMPARATOR
Intervention: White petrolatum (standard of care)
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Scar product
Number of subjects: 28
Study: 22013378

Group type: EXPERIMENTAL
Intervention: Instruction by video using the iPod Touch
Number of subjects: 22

Group type: COMPARATOR
Intervention: No instruction by video
Number of subjects: 22
Study: 19462698

Group type: EXPERIMENTAL
Intervention: Depressed patients in the same NYHA class
Number of subjects: 1495

Group type: EXPERIMENTAL
Intervention: Depression assessment
Number of subjects: 1495
Study: 17580596

Group type: EXPERIMENTAL
Intervention: Indiplon 10 mg
Number of subjects: 702

Group type: EXPERIMENTAL
Intervention: Indiplon 20 mg
Number of subjects: 702

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 702
Study: 15197199

Group type: EXPERIMENTAL
Intervention: High-fiber, low-fat diet intervention
Number of subjects: 291
Study: 11404233

Group type: EXPERIMENTAL
Intervention: Exendin-4 (0.05 pmol·kg‐1·min‐1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 0
Study: 9715049

Group type: EXPERIMENTAL
Intervention: Transanal ileal pouch-anal anastomosis (T-IAA)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Double-stapled ileal pouch-anal anastomosis (DS-IAA)
Number of subjects: 37
Study: 8038353

Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 2923591

Group type: EXPERIMENTAL
Intervention: Atropine sulfate (2 mg)
Number of subjects: 4

Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 4
Study: 31866082

Group type: EXPERIMENTAL
Intervention: New-onset postoperative atrial fibrillation (POAF)
Number of subjects: 551
Study: 30278560

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine (1.0 μg/kg over 10 min) followed by maintenance (0.5 μg/kg/h)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Midazolam (0.05 mg/kg) followed by dexmedetomidine maintenance (0.5 μg/kg/h)
Number of subjects: 40
Study: 28393775

Group type: EXPERIMENTAL
Intervention: Fentanyl (1 mcg/kg bolus followed by 1 mcg/kg/h infusion)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Sufentanil (0.1 mcg/kg bolus followed by 0.1 mcg/h infusion)
Number of subjects: 60
Study: 26152838

Group type: EXPERIMENTAL
Intervention: Pseudoephedrine hydrochloride
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lactose placebo
Number of subjects: 20
Study: 23207730

Group type: EXPERIMENTAL
Intervention: High-protein toothpaste
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Low-protein toothpaste
Number of subjects: 16

Group type: COMPARATOR
Intervention: Non-protein (placebo) toothpaste
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water brushing
Number of subjects: 16
Study: 21613795

Group type: EXPERIMENTAL
Intervention: HD200 (200 mg/dl)
Number of subjects: 23

Group type: COMPARATOR
Intervention: HD100 (100 mg/dl)
Number of subjects: 23
Study: 18362317

Group type: EXPERIMENTAL
Intervention: Removal of dental amalgam only
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removal in combination with a 'biological detoxification' therapy with high doses of vitamins and trace elements
Number of subjects: 90

Group type: COMPARATOR
Intervention: Health promotion program without removal of dental amalgam
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Removal groups (both removal and removal-plus)
Number of subjects: 90
Study: 16523309

Group type: EXPERIMENTAL
Intervention: DISA SPECT (with 99mTc-sestamibi and 18F-FDG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PET (with 13N-ammonia and 18F-FDG)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: DISA SPECT
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: PET
Number of subjects: 47
Study: 15000440

Group type: EXPERIMENTAL
Intervention: BCAA (14.4 g/day)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo (isocaloric)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: BCAA (14.4 g/day) for 30 days
Number of subjects: 22
Study: 11061609

Group type: EXPERIMENTAL
Intervention: I-CHOPE regimen (doxorubicin 10 mg/m2/day, vincristine 0.28 mg/m2/day, etoposide 48 mg/m2/day, cyclophosphamide 750 mg/m2 on day 6, prednisone 100 mg/day on days 1-5)
Number of subjects: 29
Study: 9569783

Group type: EXPERIMENTAL
Intervention: Combined root surface conditioning with tetracycline HCI, fibrin sealing system, guided tissue regeneration procedure and coronal sliding flap application
Number of subjects: 10

Group type: COMPARATOR
Intervention: Coronal sliding flap operation (Control group)
Number of subjects: 10
Study: 8096670

Group type: EXPERIMENTAL
Intervention: Nifedipine GITS
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Diltiazem
Number of subjects: 20

Group type: COMPARATOR
Intervention: Beta blockers alone
Number of subjects: 20
Study: 3927954

Group type: EXPERIMENTAL
Intervention: 15 micrograms kg‐1 extradural
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 30 micrograms kg‐1 extradural
Number of subjects: 18

Group type: COMPARATOR
Intervention: 15 micrograms kg‐1 i.m.
Number of subjects: 18
Study: 31838498

Group type: EXPERIMENTAL
Intervention: TTV viremia in Down syndrome (DS) population
Number of subjects: 1813

Group type: COMPARATOR
Intervention: TTV viremia in offspring of centenarians (GO) population
Number of subjects: 1813

Group type: COMPARATOR
Intervention: TTV viremia in spouses of GO (SGO) population
Number of subjects: 1813

Group type: COMPARATOR
Intervention: TTV viremia in randomly recruited age‐stratified individuals (RASIG) population
Number of subjects: 1813

Group type: EXPERIMENTAL
Intervention: TTV loads ≥4log copies/ml in males
Number of subjects: 1813

Group type: COMPARATOR
Intervention: TTV loads in the general population
Number of subjects: 1813
Study: 28193583

Group type: EXPERIMENTAL
Intervention: 7 mg nicotine patch
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 26026105

Group type: EXPERIMENTAL
Intervention: AGO-positive group (n=139)
Number of subjects: 209

Group type: COMPARATOR
Intervention: AGO-negative group (n=70)
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: AGO-positive patients with complete resection
Number of subjects: 209

Group type: COMPARATOR
Intervention: AGO-negative patients with complete resection
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both groups after complete resection
Number of subjects: 209

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 209
Study: 23350920

Group type: EXPERIMENTAL
Intervention: Diabetes self-management interventions
Number of subjects: 85
Study: 21452066

Group type: EXPERIMENTAL
Intervention: Laparoscopic-assisted colectomy (LAC)
Number of subjects: 449

Group type: COMPARATOR
Intervention: Open colectomy
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Baseline support
Number of subjects: 449

Group type: EXPERIMENTAL
Intervention: Baseline outlook
Number of subjects: 449
Study: 19647928

Group type: EXPERIMENTAL
Intervention: Intravenous thrombolysis (rtPA)
Number of subjects: 156
Study: 17370487

Group type: EXPERIMENTAL
Intervention: Acupoint injection at cervical Jiaji points and routine acupuncture
Number of subjects: 70

Group type: COMPARATOR
Intervention: Routine acupuncture
Number of subjects: 70
Study: 12740311

Group type: COMPARATOR
Intervention: Alcohol-displacement (A) diet (1.5 g/kg alcohol displacing CHO energy from control)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Alcohol + CHO (AC) diet (Control + 1.5 g/kg alcohol)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Control (C) diet (meals providing carbohydrate (CHO) of 1.75 g/kg)
Number of subjects: 15
Study: 10225813

Group type: EXPERIMENTAL
Intervention: Sulphasalazine (SSZ)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Auranofin (AUR)
Number of subjects: 200
Study: 8648356

Group type: EXPERIMENTAL
Intervention: CVUft group (cisplatin 50 mg/m2, vindesine 2 to 3 mg/kg for three courses, and 1-year oral administration of tegafur plus uracil 400 mg/kg)
Number of subjects: 323

Group type: EXPERIMENTAL
Intervention: Uft group (1-year oral administration of UFT 400 mg/kg)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Control group (surgical treatment only)
Number of subjects: 323

Group type: COMPARATOR
Intervention: CVUft group vs Control group
Number of subjects: 323

Group type: COMPARATOR
Intervention: Uft group vs Control group
Number of subjects: 323

Group type: COMPARATOR
Intervention: CVUft group vs Control group (Cox model)
Number of subjects: 323

Group type: COMPARATOR
Intervention: Uft group vs Control group (Cox model)
Number of subjects: 323
Study: 1984192

Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine (n = 25)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 47
Study: 6135989

Group type: EXPERIMENTAL
Intervention: Aspirin (324 mg in buffered solution daily for 12 weeks)
Number of subjects: 1266

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1266
Study: 3000793

Group type: EXPERIMENTAL
Intervention: Propranolol 240 mg
Number of subjects: 6

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study: 31047591

Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Dexamethasone implant (Ozurdex)
Number of subjects: 47
Study: 27555178

Group type: EXPERIMENTAL
Intervention: Clonidine 1 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 0.5 μg/kg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine 1 μg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 0
Study: 24121920

Group type: EXPERIMENTAL
Intervention: Intra-oral electrostimulator (GenNarino)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Sham-device
Number of subjects: 6
Study: 22976167

Group type: EXPERIMENTAL
Intervention: Ergonomic intervention (hand air pipe)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Control (standard blowing pipe)
Number of subjects: 100
Study: 19297221

Group type: EXPERIMENTAL
Intervention: Intravenous lorazepam (0.1 mg/kg)
Number of subjects: 178

Group type: COMPARATOR
Intervention: Intravenous diazepam (0.2 mg/kg) - phenytoin (18 mg/kg) combination
Number of subjects: 178
Study: 18684843

Group type: EXPERIMENTAL
Intervention: Physical training (twice-weekly 50-min sessions for 12 weeks)
Number of subjects: 34

Group type: COMPARATOR
Intervention: Control group (no physical training)
Number of subjects: 34
Study: 16147845

Group type: EXPERIMENTAL
Intervention: Spatiotemporal Image Correlation (STIC) technique for obtaining LVOT images
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Spatiotemporal Image Correlation (STIC) technique for obtaining RVOT images
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Intraobserver agreement analysis for LVOT images
Number of subjects: 20
Study: 14705720

Group type: EXPERIMENTAL
Intervention: Enoxaparin (40 mg subcutaneously once daily for 10 days)
Number of subjects: 170

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study: 10877418

Group type: EXPERIMENTAL
Intervention: Full-strength gadodiamide (0.11-0.25 mmol/kg)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Half-strength iodinated contrast material (300 mg/mL iodine)
Number of subjects: 25
Study: 8976353

Group type: EXPERIMENTAL
Intervention: Primary Closure (PC)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Polytetrafluoroethylene Patch Closure (PTFE‐PC)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (SVP and JVP)
Number of subjects: 399

Group type: COMPARATOR
Intervention: All patching (vein and PTFE)
Number of subjects: 399

Group type: COMPARATOR
Intervention: Vein Patch Closure
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (SVP)
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Vein Patch Closure (JVP)
Number of subjects: 399
Study: 1468239

Group type: EXPERIMENTAL
Intervention: 600 mg etodolac SR once daily for 4 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: 100 mg diclofenac SR
Number of subjects: 64
Study: 6478435

Group type: EXPERIMENTAL
Intervention: Multimodal therapy (2 courses of chemotherapy: cisplatin 2 mg/kg; methotrexate 280‐560 mg/m2 with leucovorin rescue; bleomycin 30 mu X 3) followed by radiation therapy and surgery
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Multimodal therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Combined therapy (preoperative radiation therapy followed by surgery)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Combined therapy
Number of subjects: 58

Group type: COMPARATOR
Intervention: Responses to therapy in combined therapy
Number of subjects: 58
Study: 31067089

Group type: EXPERIMENTAL
Intervention: 2-way SMS with a nurse
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (no SMS)
Number of subjects: 260
Study: 30383859

Group type: EXPERIMENTAL
Intervention: Childhood sexual abuse (CSA)
Number of subjects: 1002

Group type: COMPARATOR
Intervention: Concurrently experiencing 2 or more syndemic factors
Number of subjects: 1002
Study: 27175601

Group type: EXPERIMENTAL
Intervention: High-cadence (HC) interval training (20% above FCC)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-cadence (LC) interval training (20% below FCC)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: High-cadence (HC) interval training
Number of subjects: 16

Group type: COMPARATOR
Intervention: Low-cadence (LC) interval training
Number of subjects: 16
Study: 25306809

Group type: EXPERIMENTAL
Intervention: TUERP
Number of subjects: 630

Group type: COMPARATOR
Intervention: TURP
Number of subjects: 630

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 630